{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:04:11Z","timestamp":1782979451734,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03158-y","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T19:40:48Z","timestamp":1742672448000},"page":"2369-2384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical Trials"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7184-8776","authenticated-orcid":false,"given":"Yuki","family":"Otani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-3822","authenticated-orcid":false,"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-4046","authenticated-orcid":false,"given":"Geert R.","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-5764","authenticated-orcid":false,"given":"Nathan J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0549-5455","authenticated-orcid":false,"given":"Christopher D.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-129X","authenticated-orcid":false,"given":"Michelle","family":"Ugolini Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4064-6805","authenticated-orcid":false,"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"11","key":"3158_CR1","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","volume":"36","author":"I Usach","year":"2019","unstructured":"Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986\u201396.","journal-title":"Adv Ther"},{"issue":"5","key":"3158_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11095-021-03047-3","volume":"38","author":"GH Shi","year":"2021","unstructured":"Shi GH, Pisupati K, Parker JG, et al. Subcutaneous injection site pain of formulation matrices. Pharm Res. 2021;38(5):779\u201393.","journal-title":"Pharm Res"},{"key":"3158_CR3","doi-asserted-by":"crossref","unstructured":"Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40\u00a0mg\/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3(2):257\u201370.","DOI":"10.1007\/s40744-016-0041-3"},{"issue":"6","key":"3158_CR4","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","volume":"39","author":"S Chabra","year":"2022","unstructured":"Chabra S, Gill BJ, Gallo G, et al. Ixekizumab citrate-free formulation: results from two clinical trials. Adv Ther. 2022;39(6):2862\u201372.","journal-title":"Adv Ther"},{"key":"3158_CR5","unstructured":"Eli Lilly and Company. Omvoh\u2122 prescribing information [revised 1\/2025]. https:\/\/pi.lilly.com\/us\/omvoh-uspi.pdf. Accessed 13 Mar 2025."},{"issue":"12","key":"3158_CR6","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/ibd\/izae024","volume":"30","author":"BE Sands","year":"2024","unstructured":"Sands BE, D\u2019Haens G, Clemow DB, et al. Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflamm Bowel Dis. 2024;30(12):2245\u201358.","journal-title":"Inflamm Bowel Dis"},{"issue":"26","key":"3158_CR7","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444\u201355.","journal-title":"N Engl J Med"},{"issue":"10470","key":"3158_CR8","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, D\u2019Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase\u00a03, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404(10470):2423\u201336.","journal-title":"Lancet"},{"issue":"7","key":"3158_CR9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1365-2702.2005.01121.x","volume":"14","author":"A Williamson","year":"2005","unstructured":"Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14(7):798\u2013804.","journal-title":"J Clin Nurs"},{"issue":"10","key":"3158_CR10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40262-023-01281-z","volume":"62","author":"L Chua","year":"2023","unstructured":"Chua L, Friedrich S, Zhang XC. Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase\u00a0III LUCENT studies. Clin Pharmacokinet. 2023;62(10):1479\u201391.","journal-title":"Clin Pharmacokinet"},{"key":"3158_CR11","doi-asserted-by":"crossref","unstructured":"Sands BE, D\u2019Haens G, Clemow DB, et al. Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflamm Bowel Dis. 2024;izae253.","DOI":"10.1093\/ibd\/izae253"},{"issue":"3","key":"3158_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/bja\/aew466","volume":"118","author":"PS Myles","year":"2017","unstructured":"Myles PS, Myles DB, Galagher W, et al. Measuring acute postoperative pain using the visual analog scale: the minimal clinically important difference and patient acceptable symptom state. Br J Anaesth. 2017;118(3):424\u20139.","journal-title":"Br J Anaesth"},{"key":"3158_CR13","doi-asserted-by":"crossref","unstructured":"Ahn SS, Lee M, Baek Y, Lee S. A Randomized pharmacokinetic study in healthy male subjects comparing a high-concentration, citrate-free SB5 formulation (40 mg\/0.4 ml) and prior SB5 (adalimumab biosimilar). Rheumatol Ther. 2022;9(4):1157\u201369.","DOI":"10.1007\/s40744-022-00471-8"},{"issue":"2","key":"3158_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000016","volume":"1","author":"AS Patel","year":"2020","unstructured":"Patel AS, Luu P. Changes in patient reported pain measures with the citrate-free adalimumab formulation in pediatric inflammatory bowel disease patients. JPGN Rep. 2020;1(2):e016.","journal-title":"JPGN Rep"},{"issue":"1","key":"3158_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.gastrohep.2019.06.008","volume":"43","author":"C Gely","year":"2020","unstructured":"Gely C, Marin L, Gordillo J, et al. Impact of pain associated with the subcutaneous administration of adalimumab. Gastroenterol Hepatol. 2020;43(1):9\u201313.","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"3158_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40744-020-00256-x","volume":"8","author":"M Bergman","year":"2021","unstructured":"Bergman M, Patel P, Chen N, Jing Y, Saffore CD. Evaluation of adherence and persistence differences between adalimumab citrate-free and citrate formulations for patients with immune-mediated diseases in the United States. Rheumatol Ther. 2021;8(1):109\u201318.","journal-title":"Rheumatol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03158-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03158-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03158-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:50:54Z","timestamp":1744872654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03158-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3158"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03158-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuki Otani, Rodrigo Escobar, Nathan J. Morris, Christopher D. Payne, Michelle Ugolini Lopes, and Xin Zhang are employees and shareholders of Eli Lilly and Company. Brian G. Feagan has received consulting fees from AbbVie, Abivax, Adiso, AgomAB Therapeutics, Akros, Alira Health, Ally Bridge Group, AnaptysBio, Apini Therapeutics, Argenx, Avoro Capital Advisors, Belmore Law, BioFactura, BioJamp, Biora Therapeutics, Blackbird Laboratories, Boehringer Ingelheim, Boxer Capital, Celsius Therapeutics, Celgene\/BMS, Celltrion, Clarivate, Connect BioPharma, Disc Medicine, Duality, EcoR1, Eli Lilly, Ensho Therapeutics, Evida, Enveda, Faes Farma, First Wave, Forbion, Galapagos, Galen Atlantica, Genentech\/Roche, General Atlantic, Genesis Therapeutics, Gilead, Gossamer Pharma, GSK, Imhotex, ImmiDomics, Immunic Therapeutics, Intercept, Janssen, Japan Tobacco Inc., Klick Health, LifeMine Therapeutics, Mage Biologics, Merck, Mestag, Mirador Therapeutics, Mobius, Monte Rosa Tx, Morphic Therapeutics, Nexys Therapeutics, Nighthawk Therapeutics, Nimbus Therapeutics, Novartis, OncoC4, OrbiMed, Orphagen, Pendopharm, Pfizer, Protagonist,32 Bio, REDX, Roche, Roivant\/Televant, Sanofi, Sobi, Sorriso, Spyre Therapeutics, Surrozen Inc., Sun Pharma, Synedgen, Takeda, Teva, Triastek, Trex Bio, TR1X Inc. TVM Lifesciences, Ventyx Biosciences, Versant Ventures, Vida Ventures, Zagbio; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Takeda, Janssen, Pfizer, Eli Lilly; payment for expert testimony from Belmore Law; participation on a Data Safety Monitoring Board or Advisory Board for AbbVie, AnaptysBio, Boehringer Ingelheim, Celgene\/BMS, Eli Lilly, Genentech\/Roche, Janssen, Merck, MiroBio, Origo BioPharma, Pfizer, REDX Pharma, Sanofi, Takeda, Teva, Ecor1Capital, Morphic, GSK; and stock options from Connect BioPharma, EnGene. Geert R. D\u2019Haens has served as adviser and\/or speaker for Abbvie, Alimentiv, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Galapagos, Glaxo Smith Kline, Immunic, Index Pharmaceuticals, Johnson and Johnson, Merck, Polpharm, Prometheus biosciences, Prometheus Laboratories, Procise diagnostics, Protagonist, Sandoz, Takeda, Tillotts, and Ventyx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The studies were conducted in accordance with the study protocols and with consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonisation Good Clinical Practice Guidelines, and applicable laws and regulations. The study protocols were approved by the institutional review boards before all studies were initiated. Ethical review boards were in place for all studies: the WCG \u2013 Midlands Independent Review Board and WCG Independent Review Board were the overall (\u201cmaster\u201d) ethics committees for study\u00a0A, and the Salus Institutional Review Board was the overall (\u201cmaster\u201d) ethics committee for studies B and C. Informed consent forms, required to provide details about why the research was being done and what it would involve, were approved by the respective review boards and provided to participants. Subsequent dated written informed consent was required by each participant before the participant could participate in the study. The informed consent forms also noted that study data which did not directly identify participants could be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}